Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-1517

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-1517). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 1517 9

Label for Losartan Potassium 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label indicates a package containing 90 tablets for oral use. It includes dosage instructions and warnings, manufacturer details from Zhejiang Huahai Pharm. Co., Ltd. in China, and storage conditions at controlled temperatures between 59-86°F. The label is marked Rx Only.*

FDA Label Image

Structural Formula (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 01)

Chemical structure of losartan potassium, depicting its molecular framework with heterocyclic rings, chlorine atom, hydroxymethyl group, phenyl rings, and a potassium ion.*

FDA Label Image

Figure 1 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 02)

A line graph comparing the percentage of patients with a primary endpoint over 66 months between two treatments: Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows a lower percentage for Losartan Potassium. Annotations indicate an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Figure 2 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months. The graph contrasts the outcomes for patients treated with Losartan Potassium versus Atenolol, showing a lower percentage for Losartan Potassium. The chart notes an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 04)

A comparative hazard ratio chart showing primary composite and stroke (fatal/non-fatal) event rates for Losartan Potassium versus Atenolol across various patient subgroups including age, gender, race, ischemic heart disease presence, diabetes status, and cardiovascular disease history. The chart visualizes hazard ratios with confidence intervals indicating the favorability of each drug, with symbols sized proportionally to sample size.*

FDA Label Image

Losartan (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 05)

A line graph showing the percentage of patients with an event over 48 months comparing Losartan Potassium (solid line) and Placebo (dotted line). The graph indicates a risk reduction of 16.1% with Losartan Potassium and a p-value of 0.022.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.